This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): IMR687, IMR 687
IMR-687 is a highly potent, selective inhibitor of phosphodiesterase-9 (PDE9i) in blood cells. The company expects that decreased PDE9 activity will increase cGMP, a mechanism also targeted by hydroxyurea. IMR-687 was developed to target the same biochemical pathway as hydroxyurea, a chemotherapeutic agent, but without its safety issues.
The company reports that MR-687 has been shown in cell and animal models to increase fetal globin, which prevents the polymerization of the sickled hemoglobin. They note that this reduces red blood cell sickling, reduces red blood cell death and reduces occlusion of blood vessels. PDE9 inhibition also reduces white blood cell “stickiness” which further reduces the blockage of blood vessels.
Additional information available to subscribers only: